Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 6 mechanisms across 31 industry trials with a known mechanism of action.

See full pipeline →

Erythropoietin Receptor

13 trials 3 sponsors

Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor

10 trials 1 sponsor

Erythropoiesis-stimulating Agent

5 trials 2 sponsors

Interferon alpha

1 trials 1 sponsor

Thalidomide Analog

1 trials 1 sponsor

Parenteral Iron Replacement

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

142 industry-sponsored trials across 48 sponsors

Showing 15 of 15 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pharmanutra S.p.a.	Ferric Maltol (Feraccru®)	—	RECRUITING	2026-05	NCT07308769
Bristol-Myers Squibb	Luspatercept	—	ACTIVE NOT RECRUITING	2028-12-16	NCT05891249
Laboratoire Innotech International	TOT'HEMA	—	COMPLETED	2023-10-06	NCT04309669
Roche	Methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2018-04-23	NCT01191983
Amgen	Epoetin alfa	Erythropoietin Receptor	COMPLETED	2016-04-27	NCT02253654
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2013-01	NCT01156363
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2012-11-30	NCT01342640
Roche	Pegasys	Interferon alpha [EPC]	COMPLETED	2011-11	NCT00560274
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2010-11-30	NCT00922116
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2010-07	NCT00922610
Roche	methoxy polyethylene glycol-epoetin beta	Erythropoietin Receptor	COMPLETED	2009-12-31	NCT00642668
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2009-10	NCT00737711
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2009-09-12	NCT00737464
Amgen	Peginesatide	—	TERMINATED	2013-03	NCT01737879
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	TERMINATED	2011-09-30	NCT01066000

Showing 65 of 65 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Takeda	Elritercept	—	RECRUITING	2029-04-30	NCT07422480
Biocad	BCD-131 (pegdarbepoetin beta)	—	RECRUITING	2026-05	NCT07119372
Cerus Corporation	—	—	ACTIVE NOT RECRUITING	2026-07-31	NCT03037164
Bristol-Myers Squibb	ACE-536	—	ACTIVE NOT RECRUITING	2025-05-26	NCT04717414
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL-0951 tablets	—	COMPLETED	2024-06-17	NCT06720025
Shield Therapeutics	Ferric Maltol	—	COMPLETED	2024-06-09	NCT05126901
Cerus Corporation	—	—	COMPLETED	2023-12-04	NCT03459287
Kyntra Bio	FG-4592	—	COMPLETED	2023-01-11	NCT03303066
Nanogen Pharmaceutical Biotechnology Joint Stock Company	Stimus (NNG-DEPO)	—	COMPLETED	2022-11-23	NCT05585645
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2021-11-26	NCT04313153
Zydus Lifesciences Limited	Desidustat Oral Tablet	—	COMPLETED	2021-08-25	NCT04012957
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-06-18	NCT02680574
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-06-04	NCT02648347
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-01-31	NCT02865850
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-01-16	NCT02892149
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2019-08-07	NCT03543657
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2019-07-25	NCT03418168
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2019-07-05	NCT03350347
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2019-05-17	NCT03350321
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2018-10-23	NCT03351166
AstraZeneca	Roxadustat	—	COMPLETED	2018-10-04	NCT02174627
AstraZeneca	Roxadustat	—	COMPLETED	2018-09-26	NCT02174731
Kissei Pharmaceutical Co., Ltd.	JR-131	—	COMPLETED	2018-03	NCT02912533
Kissei Pharmaceutical Co., Ltd.	JR-131	—	COMPLETED	2017-09	NCT02912494
Astellas Pharma Europe B.V.	Roxadustat	—	COMPLETED	2017-06-08	NCT02278341
Kyntra Bio	FG-4592	—	COMPLETED	2017-01-24	NCT02652819
Kyntra Bio	FG-4592	—	COMPLETED	2017-01-24	NCT02652806
Biocad	Darbepoetin alfa	Erythropoiesis-stimulating Agent [EPC]	COMPLETED	2017-01-08	NCT02506868
Novartis	HX575 epoetin alfa	—	COMPLETED	2014-05	NCT01693029
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2013-03-17	NCT01029262
Takeda	Epoetin	—	COMPLETED	2013-02	NCT01478971
Amgen	darbepoetin alfa	Erythropoiesis-stimulating Agent [EPC]	COMPLETED	2012-04	NCT00925587
Roche	Methoxy polyethylene glycol-epoetin beta	Erythropoietin Receptor	COMPLETED	2011-07-31	NCT00737477
Roche	Methoxy Polyethylene Glycol-epoetin Beta	Erythropoietin Receptor	COMPLETED	2011-07	NCT00717821
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2010-12	NCT00560404
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2010-12	NCT00661388
Roche	epoetin beta	—	COMPLETED	2010-12	NCT00773331
Roche	Methoxy polyethylene glycol-epoetin beta	Erythropoietin Receptor	COMPLETED	2010-11	NCT00660023
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2010-10	NCT00882713
Roche	Methoxy Polyethylene Glycol-epoetin Beta	Erythropoietin Receptor	COMPLETED	2010-08	NCT00642967
Roche	Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)	—	COMPLETED	2010-07	NCT00699348
Roche	methoxy polyethylene glycol-epoetin beta	Erythropoietin Receptor	COMPLETED	2010-06-22	NCT00661505
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	COMPLETED	2010-06	NCT00576303
Roche	Methoxy polyethylene glycol-epoetin beta	Erythropoietin Receptor	COMPLETED	2010-06	NCT00559637
Roche	methoxy polyethylene glycol-epoetin beta [C.E.R.A.]	—	COMPLETED	2010-03	NCT00576628
Roche	Methoxy Polyethylene Glycol-Epoetin Beta	Erythropoietin Receptor	COMPLETED	2010-03	NCT00773968
American Regent, Inc.	Ferric Carboxymaltose	—	COMPLETED	2010-01	NCT00704028
Roche	methoxy polyethylene glycol-epoetin beta	Erythropoietin Receptor	COMPLETED	2010-01	NCT00605293
Roche	methoxy polyethylene glycol-epoetin beta [C.E.R.A.]	—	COMPLETED	2009-12-09	NCT00642304
Vifor Pharma	Ferric carboxymaltose	—	COMPLETED	2009-12	NCT00810030
American Regent, Inc.	Ferric Carboxymaltose (FCM)	—	COMPLETED	2009-07	NCT00703937
American Regent, Inc.	Ferric Carboxymaltose	—	COMPLETED	2009-07	NCT00704353
Chugai Pharmaceutical	epoetin beta	—	COMPLETED	2009-05	NCT00628043
Kyntra Bio	Roxadustat	—	TERMINATED	2023-03-09	NCT03263091
Amgen	Darbepoetin alfa	Erythropoiesis-stimulating Agent [EPC]	TERMINATED	2017-06-07	NCT00858364
Azidus Brasil	Epoetin alpha	—	TERMINATED	2014-12	NCT01695759
Amgen	Darbepoetin Alfa	Erythropoiesis-stimulating Agent [EPC]	TERMINATED	2014-03-03	NCT00436748
Roche	Methoxy Polyethylene Glycol-epoetin Beta	Erythropoietin Receptor	TERMINATED	2011-04	NCT00462384
Roche	methoxy polyethylene glycol-epoetin beta [Mircera]	—	TERMINATED	2010-01	NCT00680563
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Epoetin alfa	Erythropoietin Receptor	TERMINATED	2010-01	NCT00695396
Repros Therapeutics Inc.	Proellex 25 mg	—	TERMINATED	2009-08	NCT00702702
Repros Therapeutics Inc.	Proellex 25 mg	—	TERMINATED	2009-08	NCT00785356
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	WITHDRAWN	2018-02-12	NCT03242967
Targeted Medical Pharma	RBCPF	—	WITHDRAWN	2014-05	NCT01701531
Novartis	HX575 solution for s.c. administration	—	WITHDRAWN	2009-08	NCT00869856

Showing 46 of 46 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Disc Medicine, Inc	DISC-0974	—	RECRUITING	2026-09	NCT05320198
Disc Medicine, Inc	DISC-0974	—	RECRUITING	2026-10	NCT07368972
Bristol-Myers Squibb	Luspatercept	—	RECRUITING	2027-07-16	NCT05664737
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL-0951 tablets 4mg	—	RECRUITING	2025-12-31	NCT06737081
Incyte Corporation	INCB000928	—	ACTIVE NOT RECRUITING	2025-04-01	NCT04455841
Hansoh BioMedical R&D Company	HS-20106	—	NOT YET RECRUITING	2025-10-30	NCT06594965
Bristol-Myers Squibb	Luspatercept	—	COMPLETED	2022-07-18	NCT03194542
Roche	Mircera	Erythropoietin Receptor	COMPLETED	2021-07-19	NCT03552393
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-06-05	NCT03799627
Kyntra Bio	Roxadustat	—	COMPLETED	2019-12-12	NCT01630889
Novo Nordisk	COR-001	—	COMPLETED	2018-12-11	NCT02868229
Biocad	BCD-131	—	COMPLETED	2018-12-01	NCT03519243
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Luspatercept	—	COMPLETED	2018-10-22	NCT01749514
Merck	Sotatercept	—	COMPLETED	2018-04-30	NCT01736683
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2017-10-24	NCT03054350
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2017-07-04	NCT03054337
Genexine, Inc.	GX-E2	—	COMPLETED	2017-04-20	NCT02044653
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2016-11-15	NCT02055482
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2016-10-19	NCT02064426
Bristol-Myers Squibb	Sotatercept	—	COMPLETED	2016-08-31	NCT01999582
Bristol-Myers Squibb	Sotatercept	—	COMPLETED	2016-03-07	NCT01146574
TME Pharma AG	Lexaptepid pegol (NOX-H94)	—	COMPLETED	2015-11	NCT02079896
Bayer	Molidustat (BAY 85-3934)	—	COMPLETED	2015-10-23	NCT01975818
Bayer	BAY85-3934	—	COMPLETED	2015-10-15	NCT02021409
Bayer	BAY85-3934	—	COMPLETED	2015-09-15	NCT02021370
Akebia Therapeutics	AKB-6548	—	COMPLETED	2015-07-22	NCT02260193
Akebia Therapeutics	AKB-6548	—	COMPLETED	2014-09-03	NCT01906489
Kyntra Bio	Roxadustat	—	COMPLETED	2013-01-10	NCT01414075
Kyntra Bio	Roxadustat	—	COMPLETED	2012-10-15	NCT01147666
Medgenics Medical Israel Ltd.	EPODURE (dermal Biopump for erythropoietin)	—	COMPLETED	2012-07	NCT00542568
Kyntra Bio	Roxadustat	—	COMPLETED	2012-06-13	NCT01244763
Akebia Therapeutics	AKB-6548	—	COMPLETED	2012-02-16	NCT01381094
Tarix Pharmaceuticals	TXA127	—	COMPLETED	2011-12	NCT00771810
AMAG Pharmaceuticals, Inc.	Ferumoxytol	Parenteral Iron Replacement [EPC]	COMPLETED	2011-07-19	NCT01052779
Akebia Therapeutics	AKB-6548	—	COMPLETED	2011-04-13	NCT01235936
Takeda	Peginesatide	—	COMPLETED	2010-05	NCT00752791
Takeda	Peginesatide	—	COMPLETED	2009-12	NCT00752609
Affymax	peginesatide	—	COMPLETED	2009-08	NCT00680043
Incyte Corporation	INCB000928	—	TERMINATED	2024-08-15	NCT04582539
Akebia Therapeutics	vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	TERMINATED	2018-03-21	NCT03140722
GSK	GSK1278863	—	TERMINATED	2016-03-01	NCT02075463
Medgenics Medical Israel Ltd.	Subcutan implantation of autologus skin graft after ex-vivo treatment	—	TERMINATED	2013-06	NCT01555515
Merck	Sotatercept 15 mg	—	TERMINATED	2012-09-21	NCT01284348
Merck	MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline	—	TERMINATED	2010-04	NCT00924781
Merck	MK2578	—	TERMINATED	2010-04	NCT00968617
BioAge Labs, Inc.	BGE-117	—	WITHDRAWN	2022-04	NCT04815603

Showing 16 of 16 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Ascentage Pharma Group Inc.	APG-5918	—	RECRUITING	2027-12-31	NCT05773586
Rockwell Medical Technologies, Inc.	Triferic	—	COMPLETED	2017-07	NCT02909153
Pharmacosmos A/S	Iron Isomaltoside	—	COMPLETED	2017-06-04	NCT03013439
Bio Sidus SA	Epoetin Alfa 40000 UNT/ML	—	COMPLETED	2016-09	NCT03822884
Eli Lilly	LY2787106	—	COMPLETED	2014-12	NCT01340976
Bayer	BAY85-3934	—	COMPLETED	2013-09-05	NCT01318551
Bayer	BAY85-3934	—	COMPLETED	2013-05	NCT01332942
Chong Kun Dang Pharmaceutical	NESP 60μg	—	COMPLETED	2012-12-25	NCT01685671
Chong Kun Dang Pharmaceutical	NESP 60μg	—	COMPLETED	2012-11-13	NCT01684605
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	ACE-536	—	COMPLETED	2012-09	NCT01432717
TME Pharma AG	NOX-H94	—	COMPLETED	2012-03	NCT01372137
Bayer	BAY85-3934	—	COMPLETED	2011-12	NCT01458028
Astellas Pharma Inc	roxadustat	—	COMPLETED	2010-06-07	NCT01083888
Agios Pharmaceuticals, Inc.	AG-519	—	TERMINATED	2016-12	NCT02630927
Takeda	Peginesatide	—	TERMINATED	2008-06	NCT00629876
Amgen	Darbepoetin alfa	Erythropoiesis-stimulating Agent [EPC]	WITHDRAWN	2016-11	NCT01428154

Novel Drugs by Company (New molecular entities)

AGIOS PHARMS INC 1 drug

Amgen 1 drug

HOFFMAN-LA ROCHE 1 drug

MIRCERA

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA

GERON 1 drug

AKEBIA 1 drug

Bristol-Myers Squibb 1 drug

GSK 1 drug

MOMELOTINIB DIHYDROCHLORIDE

NDA 2023

Reformulations (3 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Drug Targets

Erythropoietin Receptor 3 Cereblon 1 GnRH receptor 1 Pyruvate Kinase 1 Telomerase 1 hTR 1 HIF-prolyl-4-hydroxylases 1 TGF-β superfamily ligands 1 ACVR1 1 JAK1 1 JAK2 1 JAK2 V617F 1

Generic Drugs (1 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

LENALIDOMIDE

ZYDUS PHARMS

Drug Categories:

Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
Biosimilars: BLA-approved biologics highly similar to reference products
Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology